The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly

Paul Van Buynder, S. Konrad, J.L. Van Buynder, E. Brodkin, M. Krajden, G. Ramler, M. Bigham

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Background: Influenza is associated with a high mortality and morbidity in older adults. Vaccination remains the most effective method of preventing influenza and its consequences, however, vaccine effectiveness decreases with increasing age and increasing immunosenescence. In older adults, immunogenicity studies suggest an MF59 adjuvanted influenza vaccine (ATIV, Fluad®) may help. Methods: We evaluated the comparative effectiveness of ATIV, and unadjuvanted trivalent influenza vaccine (TIV) in reducing laboratory confirmed influenza in the elderly. Elderly in three health authorities during winter 2011-12 were included in a community based case control study design. Cases tested positive and controls tested negative for influenza. Subjects with known immunosuppression were excluded. Logistic regression was used to calculate the odds ratio of vaccination (vs. no vaccination) in cases and controls. ATIV and TIV effectiveness was described. Results: A total of 282 eligible participants were enrolled (84 cases). Almost half (136) were in a long term care facility and were 85 years of age or older (132) vaccine effectiveness decreased with increasing age. In a variety of multivariate analyses, ATIV was significantly protective at around 60% (p= 0.02), with only residence in long term care and health authority also significant. Vaccine effectiveness increased in non-long term care residents. In multivariate analyses TIV was ineffective. Conclusion: An MF59 adjuvanted vaccine provided significantly improved protection against influenza in the elderly. © 2013 The Authors.
Original languageEnglish
Pages (from-to)6122-6128
JournalVaccine
Volume31
Issue number51
DOIs
Publication statusPublished - 2013

Fingerprint

Inactivated Vaccines
Influenza Vaccines
influenza
Human Influenza
vaccines
Vaccines
Vaccination
Long-Term Care
Multivariate Analysis
long term care
vaccination
Health
Immunosuppression
Case-Control Studies
Logistic Models
Odds Ratio
Morbidity
immunosuppression
Mortality
case-control studies

Cite this

Van Buynder, P., Konrad, S., Van Buynder, J. L., Brodkin, E., Krajden, M., Ramler, G., & Bigham, M. (2013). The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine, 31(51), 6122-6128. https://doi.org/10.1016/j.vaccine.2013.07.059
Van Buynder, Paul ; Konrad, S. ; Van Buynder, J.L. ; Brodkin, E. ; Krajden, M. ; Ramler, G. ; Bigham, M. / The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. In: Vaccine. 2013 ; Vol. 31, No. 51. pp. 6122-6128.
@article{fc46949078624e619a8cf2a4b9946501,
title = "The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly",
abstract = "Background: Influenza is associated with a high mortality and morbidity in older adults. Vaccination remains the most effective method of preventing influenza and its consequences, however, vaccine effectiveness decreases with increasing age and increasing immunosenescence. In older adults, immunogenicity studies suggest an MF59 adjuvanted influenza vaccine (ATIV, Fluad{\circledR}) may help. Methods: We evaluated the comparative effectiveness of ATIV, and unadjuvanted trivalent influenza vaccine (TIV) in reducing laboratory confirmed influenza in the elderly. Elderly in three health authorities during winter 2011-12 were included in a community based case control study design. Cases tested positive and controls tested negative for influenza. Subjects with known immunosuppression were excluded. Logistic regression was used to calculate the odds ratio of vaccination (vs. no vaccination) in cases and controls. ATIV and TIV effectiveness was described. Results: A total of 282 eligible participants were enrolled (84 cases). Almost half (136) were in a long term care facility and were 85 years of age or older (132) vaccine effectiveness decreased with increasing age. In a variety of multivariate analyses, ATIV was significantly protective at around 60{\%} (p= 0.02), with only residence in long term care and health authority also significant. Vaccine effectiveness increased in non-long term care residents. In multivariate analyses TIV was ineffective. Conclusion: An MF59 adjuvanted vaccine provided significantly improved protection against influenza in the elderly. {\circledC} 2013 The Authors.",
author = "{Van Buynder}, Paul and S. Konrad and {Van Buynder}, J.L. and E. Brodkin and M. Krajden and G. Ramler and M. Bigham",
year = "2013",
doi = "10.1016/j.vaccine.2013.07.059",
language = "English",
volume = "31",
pages = "6122--6128",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "51",

}

Van Buynder, P, Konrad, S, Van Buynder, JL, Brodkin, E, Krajden, M, Ramler, G & Bigham, M 2013, 'The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly' Vaccine, vol. 31, no. 51, pp. 6122-6128. https://doi.org/10.1016/j.vaccine.2013.07.059

The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. / Van Buynder, Paul; Konrad, S.; Van Buynder, J.L.; Brodkin, E.; Krajden, M.; Ramler, G.; Bigham, M.

In: Vaccine, Vol. 31, No. 51, 2013, p. 6122-6128.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly

AU - Van Buynder, Paul

AU - Konrad, S.

AU - Van Buynder, J.L.

AU - Brodkin, E.

AU - Krajden, M.

AU - Ramler, G.

AU - Bigham, M.

PY - 2013

Y1 - 2013

N2 - Background: Influenza is associated with a high mortality and morbidity in older adults. Vaccination remains the most effective method of preventing influenza and its consequences, however, vaccine effectiveness decreases with increasing age and increasing immunosenescence. In older adults, immunogenicity studies suggest an MF59 adjuvanted influenza vaccine (ATIV, Fluad®) may help. Methods: We evaluated the comparative effectiveness of ATIV, and unadjuvanted trivalent influenza vaccine (TIV) in reducing laboratory confirmed influenza in the elderly. Elderly in three health authorities during winter 2011-12 were included in a community based case control study design. Cases tested positive and controls tested negative for influenza. Subjects with known immunosuppression were excluded. Logistic regression was used to calculate the odds ratio of vaccination (vs. no vaccination) in cases and controls. ATIV and TIV effectiveness was described. Results: A total of 282 eligible participants were enrolled (84 cases). Almost half (136) were in a long term care facility and were 85 years of age or older (132) vaccine effectiveness decreased with increasing age. In a variety of multivariate analyses, ATIV was significantly protective at around 60% (p= 0.02), with only residence in long term care and health authority also significant. Vaccine effectiveness increased in non-long term care residents. In multivariate analyses TIV was ineffective. Conclusion: An MF59 adjuvanted vaccine provided significantly improved protection against influenza in the elderly. © 2013 The Authors.

AB - Background: Influenza is associated with a high mortality and morbidity in older adults. Vaccination remains the most effective method of preventing influenza and its consequences, however, vaccine effectiveness decreases with increasing age and increasing immunosenescence. In older adults, immunogenicity studies suggest an MF59 adjuvanted influenza vaccine (ATIV, Fluad®) may help. Methods: We evaluated the comparative effectiveness of ATIV, and unadjuvanted trivalent influenza vaccine (TIV) in reducing laboratory confirmed influenza in the elderly. Elderly in three health authorities during winter 2011-12 were included in a community based case control study design. Cases tested positive and controls tested negative for influenza. Subjects with known immunosuppression were excluded. Logistic regression was used to calculate the odds ratio of vaccination (vs. no vaccination) in cases and controls. ATIV and TIV effectiveness was described. Results: A total of 282 eligible participants were enrolled (84 cases). Almost half (136) were in a long term care facility and were 85 years of age or older (132) vaccine effectiveness decreased with increasing age. In a variety of multivariate analyses, ATIV was significantly protective at around 60% (p= 0.02), with only residence in long term care and health authority also significant. Vaccine effectiveness increased in non-long term care residents. In multivariate analyses TIV was ineffective. Conclusion: An MF59 adjuvanted vaccine provided significantly improved protection against influenza in the elderly. © 2013 The Authors.

U2 - 10.1016/j.vaccine.2013.07.059

DO - 10.1016/j.vaccine.2013.07.059

M3 - Article

VL - 31

SP - 6122

EP - 6128

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 51

ER -